Tyra Biosciences, Inc. (TYRA) Stock

Tyra Biosciences, Inc. is a preclinical-stage biopharmaceutical company dedicated to advancing therapies aimed at overcoming tumor resistance and improving outcomes for cancer patients. At the forefront of its pipeline is TYRA-300, the company's lead product candidate, which stands as a selective inhibitor targeting fibroblast growth factor receptor (FGFR)3. This therapy holds promise for the treatment of muscle invasive bladder cancer, addressing a critical unmet medical need in oncology.

Beyond TYRA-300, Tyra Biosciences is actively developing a spectrum of programs targeting various FGFRs and other kinase pathways implicated in cancer progression. These include initiatives focused on FGFR2-associated intrahepatic cholangiocarcinoma, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. This diverse portfolio underscores the company's commitment to exploring innovative therapeutic approaches to combat cancer.

Tyra Biosciences leverages its proprietary SNAP platform, which facilitates rapid structural design through iterative molecular SNAPshots. This platform accelerates the identification and optimization of potential drug candidates, enhancing the efficiency and effectiveness of the company's drug discovery efforts.

Founded in 2018 and headquartered in Carlsbad, California, Tyra Biosciences continues to expand its capabilities and pursue novel therapeutic avenues aimed at transforming the treatment landscape for cancer patients worldwide.